11月5日，康希诺生物盘中上涨5.42%，报27.42港元，成交额3530.24万港元。
消息面上，公司此前披露三季报，前三季度实现营收8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%，对股价形成基本面支撑。
同时，港股生物科技板块延续强势，百济神州、信达生物、康方生物、科伦博泰生物、荣昌生物涨幅居前，带动相关个股活跃。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
11月5日，康希诺生物盘中上涨5.42%，报27.42港元，成交额3530.24万港元。
消息面上，公司此前披露三季报，前三季度实现营收8.82亿元，同比增长27.40%；归母净利润1629.13万元，同比增长12.82%，对股价形成基本面支撑。
同时，港股生物科技板块延续强势，百济神州、信达生物、康方生物、科伦博泰生物、荣昌生物涨幅居前，带动相关个股活跃。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.